海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
28件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients with mild Alzheimer's Disease (STEADFAST)
- MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE MedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: HLT Classification code 10012268 Term: Dementia (excl Alzheimer's type) System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10012296 Term: Dementia of the Alzheimer's type, with depressed mood System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10012295 Term: Dementia of the Alzheimer's type, with delusions System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10012294 Term: Dementia of the Alzheimer's type, with delirium System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10012293 Term: Dementia of the Alzheimer's type, uncomplicated System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10012292 Term: Dementia of the Alzheimer's type NOS System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10066571 Term: Progression of Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Canada, Ireland, New Zealand, South Africa, United Kingdom, United States
- 2016-06-07
Authorised
- An open-label extension study evaluating the safety and tolerability of leuco-methylthioninium dihydromesylate (LMTM) in subjects with Alzheimer's Disease or a rare form of dementia (Behavioral Variant Frontotemporal Dementia) who have completed an earlier Phase trial
- Alzheimer’s Disease and behavioral variant Frontotemporal Dementia MedDRA version: 19.0 Level: PT Classification code 10068968 Term: Frontotemporal dementia System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Belgium, Bulgaria, Canada, Croatia, Finland, France, Germany, Korea, Republic of, Malaysia, Netherlands, Romania, Russian Federation, Singapore, Spain, Taiwan, United Kingdom, United States
- 2014-08-20
Authorised
- DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL- TO-MILD ALZHEIMER’S DISEASE
- Alzheimer’s Disease (AD) MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Bulgaria, Canada, Costa Rica, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2016-05-26
Authorised
- A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease.
- Early stage of Alzheimer's Disease. MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
- Australia, Bulgaria, Czech Republic, Hungary, Poland, Romania, United States
- 2015-10-06
Authorised
- An Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease
- Alzheimer’s Disease MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Estonia, France, Germany, Greece, Guatemala, Israel, Italy, Japan, Korea, Democratic People's Republic of, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Russian Federation, Serbia, Slovakia, South Africa, Spain, Taiwan, Turkey, United Kingdom, United States
- 2017-01-03
Authorised
- This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study. The efficacy and safety of investigated drug RVT-101 at a dose of 35 mg daily when used as an adjunct treatment to stable donepezil therapy will be evaluated over a 24-week treatment period for mild to moderate Alzheimer’s disease in patients on stable therapy with donepezil.
- Alzheimer’s Disease MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Bulgaria, Canada, Chile, Croatia, Czech Republic, France, Germany, Italy, Korea, Republic of, Malaysia, Poland, Serbia, Singapore, Slovakia, Spain, United Kingdom, United States
- 2015-11-11
Authorised
- DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL- TO-MILD ALZHEIMER?S DISEASE
- Alzheimer?s Disease MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Bulgaria, Canada, Costa Rica, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2016-05-17
Authorised
- A study to demonstrate the improvement in symptoms of constipation in subjects with cancer on non-cancer related pain requiring round the clock opioid therapy.
- The intended indication is: Severe pain, which can be adequately managed only with opioid analgesics. The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut. MedDRA version: 16.1 Level: PT Classification code 10058019 Term: Cancer pain System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 16.1 Level: PT Classification code 10033371 Term: Pain System Organ Class: 10018065 - General disorders and administration site conditions
- Australia, Czech Republic, Denmark, Finland, Germany, India, Israel, Korea, Republic of, Romania, United Kingdom
- 2011-05-24
